For content

August 2024

  • News archive
  • Contact
Navamedic Logo
  • Products
    • Consumer Health
    • Prescription Medicines
    • Medical Nutrition
      • Protein
        • Phenylketonuria
        • Maple Syrup Urine Disease (MSUD)
        •  Tyrosinemia (TYR)
        • Homocystinuria
        • Methylmalonic & Propionic Acidaemia MMA/PA
        • Glutaric Aciduria (GA1)
        • Isovaleric Acidaemia
        • Urea Cycle Disorders (UCD)
      • Glycogen Storage Disease
      • Fat Metabolism
      • Renal
      • Ketogenic Diet
      • Low Protein Foods
      • Nutritional Support
    • Antibiotics
    • Supporting Initiatives
      • Lighter Together
      • In Good Company
      • MyControl
  • Partnering
    • Nordic Leader
    • In-licensing and Distribution
    • Out-licensing
    • M&A and Joint Ventures
    • Partners
  • Investors
    • Share
    • Financial Results
    • Annual Reports
    • Shareholders
    • Financial Calendar
    • Equity Research
    • General Meeting
    • Prospectus
    • Offer regarding Sensidose
  • About us
    • Quality
    • Life at Navamedic
      • Vacant Positions
    • Management Team
    • Board
    • Contact
      • Report a side effect
    • Corporate Governance
      • Articles of association
    • EFPIA Disclosure Code
  • Sustainability
  • Products
    • Consumer Health
    • Prescription Medicines
    • Medical Nutrition
      • Protein
        • Phenylketonuria
        • Maple Syrup Urine Disease (MSUD)
        •  Tyrosinemia (TYR)
        • Homocystinuria
        • Methylmalonic & Propionic Acidaemia MMA/PA
        • Glutaric Aciduria (GA1)
        • Isovaleric Acidaemia
        • Urea Cycle Disorders (UCD)
      • Glycogen Storage Disease
      • Fat Metabolism
      • Renal
      • Ketogenic Diet
      • Low Protein Foods
      • Nutritional Support
    • Antibiotics
    • Supporting Initiatives
      • Lighter Together
      • In Good Company
      • MyControl
  • Partnering
    • Nordic Leader
    • In-licensing and Distribution
    • Out-licensing
    • M&A and Joint Ventures
    • Partners
  • Investors
    • Share
    • Financial Results
    • Annual Reports
    • Shareholders
    • Financial Calendar
    • Equity Research
    • General Meeting
    • Prospectus
    • Offer regarding Sensidose
  • About us
    • Quality
    • Life at Navamedic
      • Vacant Positions
    • Management Team
    • Board
    • Contact
      • Report a side effect
    • Corporate Governance
      • Articles of association
    • EFPIA Disclosure Code
  • Sustainability
  • News archive
  • Contact
  1. Navamedic
  2. August 2024

August 2024

  • All (119)
  • Regulatory (94)
  • Non regulatory (25)

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Published: 16.08.2024

Navamedic ASA: Invitation to 2024 2nd quarter presentation

Published: 12.08.2024

Logo

Contact us

Address:

Henrik Ibsens gate 100
0255 OSLO

Postboks 2044 Vika
0125 Oslo

Telephone Norway: + 47 67 11 25 40

Telephone Sweden: + 46 31 335 11 90

Telephone Netherlands: + 31 626134613

Menu

  • Home
  • About us
  • Partnering
  • Products
  • Investors
  • Sustainability

Social Media

Privacy and cookies Delivered by: CoreTrek AS | CMS: WordPress